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SUMMARY
LZAP has been reported to inhibit cellular proliferation and clonogenic growth. Here, we report that
decreased LZAP expression promoted cellular transformation, xenograft tumor growth, and xeno-
graft tumor vascularity. Loss of LZAP also increased cellular invasion, andMMP-9 expression depen-
dent on NF-kB. LZAP directly bound to RelA, impaired serine 536 phosphorylation of RelA, increased
HDAC association with RelA, inhibited basal and stimulated NF-kB transcriptional activity, and was
found at the promoter of selective NF-kB-responsive genes. LZAP protein levels were markedly de-
creased in 32% of primary HNSCCs (n = 28) and decreased LZAP levels in primary HNSCC correlated
with increased expression of the NF-kB-regulated genes IL-8 and IkBa. In aggregate, these data sup-
port a role of LZAP in NF-kB regulation and tumor suppression.INTRODUCTION
Tumor formation is a multistep process that involves acti-
vation of oncogenes and inhibition of tumor suppressors.
At the cellular level, biologic activities of tumor suppres-
sors frequently result in cell cycle arrest or apoptosis in re-
sponse to oncogenic or mutagenic stimuli. On the other
hand, activation of oncogenes is typically associated
with cellular proliferation or protection from apoptosis.
Oncogene and tumor suppressor activity must be tightly
regulated to prevent uncontrolled proliferation and tumor
formation, but also to avoid unnecessary cell death or pro-
liferative arrest, either of which could harm the organism.
Proteins that simultaneously control activities of multi-
ple tumor suppressors and/or oncogenes can drastically
alter oncogenic potential. Some of the first examples of
proteins capable of altering multiple tumor-related targetsCancewere discovered from oncogenic viruses. The simian virus
40 large T antigen inhibits tumor suppressors p53 and ret-
inoblastoma (Rb) (Ahuja et al., 2005), and the human pap-
illoma virus E6 protein inhibits p53 and Bax (Magal et al.,
2005; Mantovani and Banks, 2001) but activates the hu-
man telomerase catalytic subunit (hTERT) (Liu et al.,
2005). More recently, endogenous proteins have been
found to regulate multiple proteins involved in tumorigen-
esis. MDM2, which inhibits and degrades p53, can also in-
hibit andmediate degradation of Rb (Ying and Xiao, 2006).
Likewise, the ARF tumor suppressor (p14ARF in human,
p19ARF in mouse) simultaneously activates p53 and in-
hibits the transcriptional activity of nuclear factor-kB
(NF-kB) (Rocha et al., 2003; Zhang et al., 1998). NF-kB
is a family of pluripotent transcription factors that play
a fundamental role in inflammatory and immune re-
sponses as well as tumorigenesis. All NF-kB proteinsSIGNIFICANCE
NF-kB is activated in a wide range of human cancers, including head and neck squamous cell carcinoma, and has
been implicated in tumor progression at least partially through promotion of invasion and angiogenesis and by
inhibition of apoptosis. Recently, tumor suppressors such as ARF and CYLD have been shown to inhibit NF-kB,
contributing to their antitumor activities. Using both in vivo and in vitro assays, we show that LZAP potently inhibits
NF-kB and has tumor suppressor-like activity. Loss of LZAP was found in one-third of primary head and neck
squamous cell carcinomas and correlated with increased expression of the NF-kB-regulated genes IL-8 and
IkBa. Loss of LZAP may represent a distinct mechanism leading to increased NF-kB activity in human tumors.r Cell 12, 239–251, September 2007 ª2007 Elsevier Inc. 239
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The Putative Tumor Suppressor LZAP Inhibits NF-kBcontain Rel homology domains that mediate DNA binding,
dimerization, and nuclear localization. Active NF-kB re-
quires dimerization of two subunits. The heterodimer of
RelA/p50 is the most intensely studied form of NF-kB
complex, and many oncogenic activities such as stimula-
tion of proliferation, angiogenesis, invasion, transforma-
tion, and inhibition of apoptosis have been attributed to
it (Karin et al., 2002). NF-kB activity is tightly and intricately
controlled, most notably through binding IkB proteins that
tether NF-kB in the cytoplasm until nuclear translocation is
induced by signal-initiated IkB degradation (Hayden and
Ghosh, 2004). It has recently been recognized that nuclear
localization alone is insufficient to fully activate NF-kB
transcription. Nuclear events including posttranslational
modification and association with transcriptional coacti-
vators are necessary for full NF-kB activation (Chen and
Greene, 2004). Association with transcriptional corepres-
sors can inhibit NF-kB transcription despite nuclear local-
ization. The discovery of nuclear regulatory events sug-
gests that NF-kB activity is not only defined by mass
translocation from the cytoplasm to the nucleus.
We previously described that LZAP activates the tumor
suppressor p53 and inhibits clonogenic growth of tumor
cell lines in vitro (Wang et al., 2006). LZAP has also been
found to promote apoptosis in response to genotoxic
agents such as etoposide through regulation of the
Cdk1-cyclinB1 complex (Jiang et al., 2005). Here, we de-
scribe additional LZAP activity as an inhibitor of NF-kB in-
dependent of ARF or p53. Depletion of LZAP increased
cellular invasion and MMP-9 expression both of which
were dependent on NF-kB and was associated with
in vitro cellular transformation. In vivo studies revealed
that diminished LZAP levels enhanced xenograft tumor
growth and angiogenesis. Loss of LZAP protein was ob-
served in approximately 30% of human head and neck
squamous cell carcinomas (HNSCC), and in these tumors,
LZAP expression inversely correlated with expression of
a subset of NF-kB target genes.
RESULTS
LZAP Protein Levels Are Dramatically Decreased
in a Portion of Human Head and Neck Squamous
Cell Carcinomas
We identified LZAP as an ARF-binding protein that acti-
vates p53 in ARF-dependent and -independent manners.
Expression of LZAP reduces cellular proliferation and
clonogenic growth of p53-positive cells (Wang et al.,
2006), and loss of LZAP protects HeLa cells from apopto-
sis induced by genotoxic agents such as etoposide or X-
ray irradiation through regulation of Cdk1-cyclinB1 (Jiang
et al., 2005). These observations led us to explore a poten-
tial tumor suppressor role for LZAP. Since many tumor
suppressors are inactivated in tumors through loss of ex-
pression, we examined LZAP protein levels in tumors and
histologically normal epithelium adjacent to tumor (NAT)
from head and neck squamous cell carcinoma (HNSCC)
patients (n = 28, 17 incident and 11 recurrent tumors). Fro-
zen tumor andNATweremacrodissected with histological240 Cancer Cell 12, 239–251, September 2007 ª2007 Elsevierguidance to ensure that the tumor and normal adjacent
tissue samples contained at least 70% epithelial cells.
LZAP levels within cancer tissue and the normal adjacent
epithelium were determined by quantification of band in-
tensity after immunoblotting and normalization to GAPDH
as a loading control. Mean LZAP levels observed in
HNSCCs were lower than those observed in normal sur-
rounding epithelia, but the mean levels differed by less
than 2-fold (Figure 1A). However, while LZAP expression
in the normal epithelia adjacent to tumors clustered in
a single group around the mean, HNSCCs could be sepa-
rated into three groups based on LZAP expression. LZAP
levels in the majority of tumors (19 of 28) clustered in a
pattern around amean similar to themean and pattern ob-
served in NAT (similar to NAT group). Nine of 28 (32%)
HNSCC had lower LZAP expression, and these tumors
were divided into subgroups based on LZAP expression.
By immunoblotting, five tumors lacked detectable bands
at the molecular weight of LZAP (undetectable LZAP
group), while another four tumors had faint LZAP bands
(trace LZAP group) by immunoblotting. Pairwise compar-
ison between individual HNSCC andNAT derived from the
same patient revealed that LZAP expression in tumors
was reduced by more than 50% in 15 of 28 tumors
(54%). Conversely, 4 of 28 tumors contained LZAP protein
levels that were elevated by more than 2-fold compared
with NAT. The remaining nine HNSCCs had LZAP levels
similar to matched NAT.
Depletion of LZAP Induces Primary Cell
Transformation In Vitro
LZAP protein was markedly decreased in a portion of pri-
mary human HNSCCs, suggesting that LZAP may have
a role in prevention of tumor formation. To determine if en-
dogenous LZAP protected against cellular transformation,
anchorage-independent growth was measured after
LZAP expression was inhibited by retrovirally delivered
shRNA in immortalized but not transformed TLM-HMEC
cells (Westbrook et al., 2005). Compared to cells infected
with control retrovirus, cells lacking LZAP had an approx-
imate 9-fold increase in colony number and produced
larger colonies (Figure 1B). Loss of LZAP expression
was confirmed in a portion of the cells prior to soft agar
plating (Figure 1B). Since p53 is inactivated in TLM-
HMEC cells by large T antigen, increased soft agar growth
associated with LZAP loss was attributable to p53-inde-
pendent activities.
Decreased LZAP Expression Promotes Xenograft
Tumor Formation
To further explore a potential role of LZAP as a tumor
suppressor, nude mice xenografts were modeled using
HeLa cells following inhibition of LZAP expression by
retrovirally delivered shRNA. HeLa cells were chosen
because they reliably form tumors in nude mice, but
not in 100% of inoculated sites, thereby enabling mea-
surements of tumor incidence as well as tumor growth.
Additionally, HeLa cells lack p53 activity, so LZAP-medi-
ated effects on tumor development could be attributedInc.
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The Putative Tumor Suppressor LZAP Inhibits NF-kBFigure 1. LZAP Has Tumor Suppressor-like Qualities
(A) LZAP is downregulated in human head and neck squamous cell carcinomas (HNSCC). Relative LZAP expression was determined by immunoblot-
ting lysate from 28 pairs of frozen HNSCCs and surrounding normal epithelia adjacent to tumor (NAT). LZAP levels were corrected for loading based
on expression of GAPDH. Mean LZAP level in NAT was set as 1. Three groups of HNSCC based on LZAP expression are defined.
(B) Depletion of LZAP expression promotes cellular transformation. TLM-HMEC cells were infected with control retrovirus or retrovirus encoding
shRNA specific to LZAP, selected by puromycin, and plated into soft agar. Colonies were counted 2 weeks after initial plating. Data were generated
from two independent experiments, each in triplicate (error bars =mean ± SD). For each experiment, ten low-powered fields (1003) were counted per
well. Loss of LZAP expression in cells prior to plating was confirmed by immunoblotting. Representative photomicrographs of TLM-HMEC colonies
are shown (scale bars, 200 mm).
(C) Decreased LZAP levels enhance xenograft tumor growth. HeLa cells were infected with either control retrovirus or retrovirus delivering LZAP-spe-
cific shRNA and selected with puromycin. Three mice (six injections) were inoculated with control HeLa cells and three with LZAP knockdown cells.
Tumor growth was monitored weekly by measurement of diameter until the largest tumor diameter approached 15 mm (error bars, mean ± SD).
(D) HeLa xenografts with diminished LZAP expression were larger than control xenografts. Tumors from two independent xenograft experimentswere
weighed immediately after removal. Mean xenograft tumor weight is indicated.
(E) Immunoblotting of LZAP in representative xenograft tumors at the time of sacrifice. Two control and two LZAP knockdown HeLa xenograft tumors
from the experiment described in Figure 1A. Tumors were macrodissected to enrich for epithelial tumor cells prior to immunoblotting.
(F) Loss of LZAP in xenograft tumors is associated with increased blood vessel density. Five micrometer sections of xenograft tumors described in
Figure 1C were immunostained with von Willebrand Factor (vWF)-specific antibodies. Mean number of vWF-positive vessels per high-powered field
(4003) and standard error are presented. Results represent vessel density determined from at least six independent high-powered fields per tumor.to p53-independent activities of LZAP. For each of two
independent experiments, six nude mice were divided
into two equal groups and inoculated with either control
cells or LZAP knockdown cells into both flanks. Com-
parison of the average tumor latency and diameter re-Cancvealed that LZAP knockdown tumors emerged earlier
and proliferated to a greater size compared to control
tumors (Figure 1C). At the end of the experimental pe-
riod, the final wet weights of LZAP knockdown tumors
were found to be markedly higher than control tumorser Cell 12, 239–251, September 2007 ª2007 Elsevier Inc. 241
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The Putative Tumor Suppressor LZAP Inhibits NF-kBFigure 2. Decreased LZAP Expression Enhances NF-kB-Dependent Cell Invasion and MMP-9 Expression
(A) Depletion of LZAP promotes cell invasion. U2OS cells were transfected with siRNA as indicated. Migration or invasion through transwells without
or with matrigel, respectively, was measured by direct counting of trespassed cells. Representative photomicrographs are shown (scale bars,
100 mm). Results represent cell counts from at least five randomly selected low-powered fields (2003) from three independent experiments (error
bars, mean ± SEM). Media containing 1% FBS in the lower chamber served as control. Immunoblotting was used to confirm LZAP expression before
seeding of cell into transwells.
(B) LZAP knockdown increasesMMP-9 expression. Levels of MMP-2 andMMP-9 in conditionedmedium derived from siRNA-transfected U2OS cells
were determined by gelatin-based zymography (lanes 1 and 2). Similar zymography was performed after infection with control or mutated IkBa-
super-repressor (IkBa-SR) expressing retroviruses as indicated (lanes 4–6).
(C) Matrigel invasion is dependent on NF-kB activity. Migration and invasion assays following transfection of siRNA as indicated were performed in
U2OS cells infected with control or IkBa-SR-encoding retrovirus. Migration and invasion were measured as described above (error bars, mean ±
SEM).(Figure 1D). Although tumor latency and tumor size were
altered by loss of LZAP expression, tumor incidence
was similar in this xenograft model (6/12 control, 7/12
LZAP knockdown). Immunoblotting of LZAP in represen-
tative xenograft tumors indicated that diminished LZAP
expression had been maintained throughout the experi-
mental time course (Figure 1E).
Upon harvesting of xenograft tumors at the completion
of the experiments, gross inspection of the tumors re-
vealed that LZAP knockdown tumors were pink, whereas
control tumors were white, suggesting that vascularity
may differ. To determine blood vessel density within tu-
mors, immunohistochemical staining of von Willebrand
Factor (vWF) followed by direct counting of blood vessels
in nonnecrotic tumor regions was performed. Blood ves-
sel density was increased roughly 4-fold in LZAP knock-
down tumors relative to control tumors (Figure 1F). Lungs
of mice bearing xenograft tumors were examined but re-242 Cancer Cell 12, 239–251, September 2007 ª2007 Elsevier Ivealed no metastases in either control or LZAP knock-
down groups (data not shown).
Depletion of Endogenous LZAP Induces
NF-kB-Dependent MMP-9 Expression
and Cell Invasion In Vitro
To provide further insight into tumor-related activities of
LZAP, in vitro cell invasion through a matrigel barrier
was measured after LZAP expression was decreased. In-
vasion was infrequent in control U2OS cells and absent
without serum as an attractant; however, following
siRNA-mediated inhibition of LZAP expression, invasion
was increased approximately 9-fold (Figure 2A). Dimin-
ished LZAP expression did not alter cellular migration
through the transwells in the absence of matrigel
(Figure 2A). Reduction of endogenous LZAP proteins
levels following transient transfection of siRNA was con-
firmed by immunoblotting (Figure 2A).nc.
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The Putative Tumor Suppressor LZAP Inhibits NF-kBFigure 3. Decreased LZAP Expression
Activates NF-kB-Mediated Transcription
(A) Depletion of LZAP increased basal NF-kB
activity. HeLa or U2OS cells were transiently
transfected with control siRNA or siRNA spe-
cific to LZAP (LZAP-1) along with a control
(conA-luc) or NF-kB-responsive (3kB-conA-
luc) luciferase reporter as indicated. Luciferase
activities were determined by the dual lucifer-
ase assay system 2 days after transfection. In
this and subsequent luciferase assays, firefly
luciferase activity was normalized to coex-
pressed renilla luciferase from the CMV pro-
moter as the internal control, and normalized
firefly luciferase activity from cells transfected
with control reagents was assigned a value of
1. All luciferase assay data are expressed as
the mean ± standard error of at least three in-
dependent experiments.
(B) Two distinct LZAP siRNAs (LZAP-1 and
LZAP-2) reduce LZAP expression and increase
NF-kB transcriptional activity. Luciferase NF-
kB reporter assays were performed after trans-
fection of U2OS cells with indicated siRNA
constructs. LZAP levels were confirmed by
immunoblotting.
(C) Decreased LZAP expression potentiates
TNFa or IL-1b activation of NF-kB. U2OS cells
were transfected with siRNA constructs as in-
dicated before luciferase assay. Untreated cells or cells treated with 10 ng/ml TNFa or 2 ng/ml IL-1b were assayed for NF-kB-dependent luciferase
activity.
(D) Luciferase activity induced by depletion of LZAP is NF-kB dependent. Transfection of siRNA constructs and subsequent luciferase assays were
performed in U2OS cells infected with control or IkBa-SR-encoding retrovirus.Matrix metalloproteinases (MMPs) comprise a family of
secreted or membrane-associated zinc-dependent extra-
cellular endopeptidases that enhance invasion and
metastases (Fingleton, 2006). To determine if increased
invasion observed with loss of LZAP expression was
associated with concomitant change of matrix metallo-
proteinase levels, gelatin-based zymography assays
measuring expression of MMP-2 and MMP-9 were per-
formed. MMP-9 levels were increased following LZAP
knockdown, whereas MMP-2 levels were not altered by
loss of LZAP (Figure 2B, lanes 1 and 2). NF-kB regulates
MMP-9 and/or MMP-2 expression in various cells (Bond
et al., 1998; He, 1996; Kim and Koh, 2000; Takada et al.,
2005). To determine if increased MMP-9 expression ob-
served in U2OS cells following loss of LZAP expression
was dependent on NF-kB, zymography assays were re-
peated in cells stably expressing a degradation-resistant
mutant of the NF-kB inhibitor IkBa (IkBa-super-repressor
[IkBa-SR]). MMP-9 activity was undetectable in the pres-
ence of IkBa-SR regardless of LZAP status, suggesting
that NF-kB activity was required for basal and LZAP-reg-
ulatedMMP-9 expression (Figure 2B, lanes 3–6). Similarly,
constitutive expression of MMP-9, as well as elevated ex-
pression associated with LZAP loss, was partially abro-
gated by simultaneous siRNA-mediated repression of
RelA expression (Figure S1A in the Supplemental Data
available with this article online). MMP-2 activity was not
altered by expression of IkBa-SR, indicating that NF-kB
was dispensable for basal MMP-2 expression in U2OSCanccells. Additionally, matrigel invasion assays in the pres-
ence of IkBa-SR or knockdown of RelA revealed that the
invasive phenotype caused by loss of LZAP was also de-
pendent on NF-kB activity (Figure 2C and Figure S1B).
Depletion of Endogenous LZAP Activates NF-kB
LZAP knockdown was associated with increased NF-kB-
dependent expression of MMP-9 (Figure 2B). To further
elucidate the effect of LZAP on NF-kB transcriptional
activity, luciferase reporter assays with an NF-kB-respon-
sive promoter (3kB-conA-luc) were performed in U2OS
and HeLa cells following treatment with LZAP-specific
siRNA. Depletion of LZAP resulted in a significant increase
of NF-kB activity relative to mock or control siRNA-trans-
fected cells (Figure 3A). In contrast, luciferase expression
from the conA-luc control reporter, which is not respon-
sive to NF-kB, was not altered by depletion of LZAP
(Figure 3A and data not shown). To exclude the possibility
that off-target effects of siRNA were responsible for acti-
vation of NF-kB, results were confirmed using an alterna-
tive siRNA targeting an independent LZAP sequence
(LZAP-2) (Figure 3B).
Cytokines such as TNFa or IL-1b rapidly and potently
activate NF-kB transcription. To determine if endogenous
LZAP regulated cytokine-induced NF-kB activation, NF-
kB activity was determined in TNFa- or IL-1b-treated cells
after siRNA-directed loss of LZAP. Loss of LZAP was as-
sociated with further enhancement of NF-kB activity fol-
lowing cytokine stimulation (Figure 3C).er Cell 12, 239–251, September 2007 ª2007 Elsevier Inc. 243
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The Putative Tumor Suppressor LZAP Inhibits NF-kBFigure 4. Overexpression of LZAP Inhibits NF-kB Transcriptional Activity
(A) LZAP inhibits NF-kB transcriptional activity. U2OS cells were transfected with plasmids encoding LZAP or IkBa-SR in addition to the NF-kB-
responsive reporter 3kB-conA-luc or the NF-kB-independent reporter conA-luc, as indicated. Two days after transfection, luciferase activities
were determined as described in Figure 3A.
(B) Expression of LZAP inhibits NF-kB transcriptional activity in 293T, HT1080, and HeLa cells. Luciferase reporter assays using the 3kB-conA-luc
reporter were performed in the three cell lines after transfection with control or LZAP plasmids as indicated.
(C) LZAP blocks NF-kB activation by cytokines or expression of RelA. Luciferase reporter assays were performed in U2OS cells following 4 hr TNFa or
IL-1b treatment with or without LZAP expression. Alternatively, 10 ng pcDNA3-Myc-RelA was cotransfected with 1 mg empty vector or DNA construct
encoding LZAP prior to luciferase reporter assays.
(D) LZAP sensitizes HT1080 cells to TNFa-induced apoptosis. HT1080 cells were transfected as indicated followed by puromycin selection and treat-
ment with indicated doses of TNFa for 24 hr. Cells were stained with trypan blue, and live cells were counted. Data presented are themean ± standard
error generated from three independent experiments.To confirm that the reporter activity measured from the
3kB-conA-Luc construct was dependent on NF-kB activ-
ity, U2OS cells were infected with retrovirus directing ex-
pression of IkBa-SR before measuring NF-kB activity.
As expected, luciferase activity was nearly undetectable
in cells stably expressing IkBa-SR regardless of LZAP sta-
tus (Figure 3D). Additionally, enhancement of NF-kB activ-
ity seen with LZAP knockdown was partially inhibited with
simultaneous knockdown of RelA (Figure S1C). Collec-
tively, these results suggest that endogenous LZAP re-
pressed both basal and cytokine-induced NF-kB activity.
LZAP Inhibits NF-kB Transcriptional Activity
To further explore the role of LZAP in regulation of NF-kB,
reporter assays were performed following expression of
LZAP. In U2OS cells, ectopic expression of LZAP inhibited
basal NF-kB transcription to a similar degree as the well-
characterized IkBa-SR (Figure 4A). Luciferase expression
from the control reporter (conA-luc) was not altered by
LZAP or IkBa-SR expression (Figure 4A). Our previous
study indicates that LZAP affects ARF and p53 activities,
both of which have been reported as NF-kB inhibitors.
To determine if LZAP activity toward NF-kB required ei-
ther ARF or p53, luciferase reporter assays were repeated
in HT1080 (human fibrosarcoma, ARF negative, p53 wild-
type), HeLa (human cervical adenocarcinoma, containing
human papilloma virus type 18 E6 and E7 proteins), and
293T (human kidney epithelial cells expressing adenoviral244 Cancer Cell 12, 239–251, September 2007 ª2007 Elsevier IE1A and E1B proteins and SV40 large T antigen) cells. In
all three cell lines, expression of LZAP reduced basal
NF-kB activity regardless of ARF or p53 status
(Figure 4B). Inhibition of NF-kB transcriptional activity
was confirmed using a different NF-kB-dependent lucifer-
ase reporter (p65-luc; data not shown). Additionally, lucif-
erase reporter assays following TNFa or IL-1b treatment
demonstrated that NF-kB activity induced by cytokines
was markedly decreased in cells expressing LZAP
(Figure 4C). Similar results were observed in three addi-
tional cell lines examined (293T, HeLa, and HT1080;
data not shown). Expression of LZAP also inhibited NF-
kB activity associated with ectopic expression of RelA
(Figure 4C).
LZAP Sensitizes HT1080 Cells to TNFa-Induced
Cell Death
Constitutive NF-kB activation within many human tumor
types promotes tumor survival following administration
of chemotherapeutic agents or in response to cytokine
stimulation. TNFa activates apoptotic pathways but rarely
results in massive cell death due to simultaneous induc-
tion of NF-kB; however, inhibition of NF-kB sensitizes
the chemoresistant HT1080 cells to TNFa-induced apo-
ptosis (Wang et al., 1996). To determine if expression of
LZAP similarly increased cytokine-induced apoptosis,
HT1080 cell survival was evaluated after treatment with
increasing concentrations of TNFa. Like IkBa-SR,nc.
Cancer Cell
The Putative Tumor Suppressor LZAP Inhibits NF-kBFigure 5. LZAP Directly Interacts with RelA
(A) Ectopically expressed LZAP and RelA mutually coimmunoprecipi-
tate. U2OS cells were transfected with indicated plasmids directing
expression of tagged LZAP or RelA. Immunoprecipitates were pre-
pared using rabbit antibodies recognizing LZAP or RelA, resolved on
SDS-PAGE, and immunoblotted by HRP-conjugated Myc or FLAG
antibodies. In this and subsequent immunoprecipitation experiments,
5% of each input lysate was loaded as reference (input).
(B) LZAP does not bind to p50. U2OS cells were transfected with plas-
mids directing expression of LZAP and p50, and lysate was immuno-
precipitated using LZAP- or p50-specific antibodies, then immuno-
blotted with HRP-conjugated antibodies specific to Myc or Flag.
(C) Endogenous LZAP binds endogenous RelA. Lysates from untrans-
fected 293T cells were immunoprecipitated with preimmune or LZAP-
specific rabbit antiserum, then immunoblotted with antibodies specific
to RelA and LZAP.
(D) Extended C-terminal portion of the Rel homology domain of RelA is
sufficient for LZAP interaction. Myc3-tagged truncation mutants of
RelA were coexpressed in U2OS cells with full-length LZAP. LZAP
was immunoprecipitated, and RelA mutants were identified by Myc
immunoblotting.Canceexpression of LZAP resulted in a dose-dependent loss of
cell viability in response to TNFa (Figure 4D).
LZAP Directly Binds to RelA
To begin exploring mechanisms by which LZAP inhibited
NF-kB, LZAP binding to NF-kB proteins was tested in
mammalian cells by coimmunoprecipitation of transiently
expressed FLAG-tagged LZAP and/or Myc-tagged RelA.
When coexpressed, LZAP was readily detected from
RelA immunoprecipitates and RelA was reciprocally co-
precipitated using LZAP antibody (Figure 5A). These
data suggest that only a portion of LZAP and RelA within
cells interact. Antibody crossreaction was not detected
from cells singly expressing either LZAP or RelA. In
contrast, coimmunoprecipitation of overexpressed LZAP
and p50 yielded no detectable interaction (Figure 5B).
RelA was detected in immunoprecipitates prepared from
untransfected 293T cells using an anti-LZAP serum but
not in precipitates using a preimmune rabbit serum (Fig-
ure 5C); however, LZAP could not be detected in the recip-
rocal immunoprecipitation using RelA-specific antibody
(data not shown).
To define the region of RelA protein required for LZAP
interaction, immunoprecipitation experiments were per-
formed using a series of RelA truncation mutants. Neither
the Rel homology domain (RHD, aa 1–313) nor the tran-
scription activation domain (TAD, aa 314–551) efficiently
bound to LZAP (Figure 5D). Further screening showed
that an extended amino-terminal region of RelA (aa 1–
350) including the RHD domain was sufficient for LZAP
binding (data not shown). Within this region, the DNA-
binding domain (aa 1–200) was unable to interact with
LZAP, whereas amino acid residues 195–350 strongly in-
teracted with LZAP (Figure 5D, lane 13). Further deletion
of this region, either at the amino (leaving aa 250–350) or
carboxyl (leaving aa 195–313) terminus, abolished the ro-
bust interaction. Longer exposure allowed detection of aa
195–313 of RelA, but not aa 250–350, associated with
LZAP (Figure 5D and data not shown).
Detection of RelA within LZAP immunoprecipitates from
cell lysates could represent direct or indirect LZAP-RelA
binding. To begin to distinguish these possibilities, we
used bacterially expressed histidine-tagged LZAP to pull
down full-length or truncation mutants of RelA generated
through cell-free in vitro transcription and translation.
Consistent with in vivo experiments, LZAP interacted
with full-length RelA, and RelA truncation mutants con-
taining aa 195–313 and aa 195–350, but not with aa
250–350 (Figure 5E, lanes 5–8). All RelA peptides were ex-
pressed well, and nickel beads without histidine-tagged
(E) LZAP binds to RelA in vitro. Myc-tagged full-length RelA and RelA
truncation mutants were synthesized by in vitro transcription/transla-
tion in the presence of 35S-methionine before incubation with bacteri-
ally expressed His6-tagged LZAP. Protein complexes bound to Ni-
NTA resin were separated by gel electrophoresis and visualized by
autoradiography. Ni-NTA resin was used as negative control. Input
corresponds to 10% of IVT proteins used for pulldown assays.r Cell 12, 239–251, September 2007 ª2007 Elsevier Inc. 245
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mal region tested capable of binding LZAP included aa
195–313; however, in vivo data suggested that extension
of RelA truncation mutant to include aa 195–350 allowed
more robust interaction with LZAP.
LZAP Does Not Interfere with Nuclear
Translocation or DNA Binding of RelA
NF-kB activity is regulated in both the cytoplasm and
nucleus. Cytoplasmic events, including sequential phos-
phorylation, polyubiquitination, and degradation of IkB
proteins, result in NF-kB nuclear translocation. To deter-
mine if inhibition of NF-kB activity observed with expres-
sion of LZAP was associated with inhibition of RelA nu-
clear translocation, subcellular localization of RelA was
determined following TNFa stimulation in cells expressing
ectopic LZAP. In cells without TNFa stimulation, RelA pro-
tein was predominately cytoplasmic regardless of the ex-
pression status of LZAP. TNFa treatment triggered RelA
nuclear accumulation in both LZAP-expressing and con-
trol cells (Figure S2A). Immunofluorescent staining of
RelA in cells transfected with LZAP-1 siRNA showed no
detectable difference in cytoplasmic RelA compared to
control cells (Figure S2B). Reduction of endogenous
LZAP expression and increase of NF-kBactivity were con-
firmed in parallel experiments (data not shown).
DNA-binding activity of NF-kB in the presence or ab-
sence of LZAP was determined using an ELISA-based
DNA-binding assay following TNFa stimulation. DNA-
bound RelA subunits were identified using specific
antibodies and visualized by chemiluminescence. As
expected, nuclear extracts prepared from U2OS cells ex-
pressing ectopic IkBa-SR contained less RelA capable of
binding DNA at all time points after TNFa stimulation.
Expression of LZAP did not significantly alter DNA-binding
activity of RelA at any time point (Figure S2C). Consistent
with DNA binding and RelA cellular localization studies,
TNFa-induced IkBa phosphorylation and IkBa protein
degradation over a time course was not significantly al-
tered by LZAP expression (Figure S2D) Collectively, our
data suggest that inhibition of NF-kB by LZAP does not
rely on altering IkBa degradation, RelA nuclear trans-
location, or RelA DNA binding.
LZAP Impairs Phosphorylation of RelA at Serine
536
Phosphorylation of RelA protein is required for its full acti-
vation. Among the several known phosphorylation sites of
RelA, serine residues 276, 529, and 536 modified by a
variety of kinases have been shown to increase DNA bind-
ing and/or transactivation (Viatour et al., 2005). To deter-
mine the effect of LZAP on RelA phosphorylation, Myc-
tagged RelA was transiently expressed in U2OS cells
with or without LZAP. Following TNFa stimulation, RelA
protein was precipitated before immunoblotting with
RelA phosphoserine-specific antibodies. Phosphorylation
at serine 536 of RelA was decreased in LZAP-expressing
cells, while phosphorylation at serines 276 and 529 were
not altered (Figure 6A). The effect of loss of LZAP expres-246 Cancer Cell 12, 239–251, September 2007 ª2007 Elsevier Ision on phosphorylation of RelA serine 536 was confirmed
by direct immunoblotting following transient transfection
of the LZAP-1 siRNA. Loss of LZAP expression correlated
with increased phosphorylation at serine 536 of RelA ei-
ther with or without IL-1b or TNFa stimulation (Figure 6B).
We next compared the effect of LZAP on the transacti-
vation of fusion proteins comprising the amino-terminal
Gal4 DNA-binding domain and carboxyl-terminal full-
length RelA (Gal4-RelA) or RelA with an activation muta-
tion at serine 536 (Gal4-RelAS536D) designed to mimic
phosphorylation at this site. Expression of LZAP inhibited
transcription mediated by Gal4-fused wild-type RelA to
a greater extent than Gal4-RelAS536D (Figure 6C). These
data indicate that LZAP inhibition of RelA is partially de-
pendent on its ability to alter phosphorylation of serine
536.
LZAP Enhances RelA Association with HDAC1,
HDAC2, and HDAC3
Recent studies have demonstrated that UV-C, doxorubi-
cin, and the tumor suppressor ARF can inhibit NF-kB ac-
tivity by increasing RelA association with histone deacety-
lases (HDACs) and conversion of NF-kB into an active
transcription repressor (Perkins, 2004). To determine if
a similar mechanism contributed to inhibition of NF- kB
by LZAP, HDAC complexes were precipitated from cells
expressing Myc-tagged RelA with or without LZAP and
immunoblotted for RelA. In LZAP-expressing cells, more
RelA protein was associated with HDAC1, HDAC2, and
HDAC3 (Figure 6D).
LZAP Regulates Expression of a Subset
of NF-kB-Responsive Genes
To determine which NF-kB-responsive genes were regu-
lated by LZAP, expression of 15 NF-kB-regulated genes
was evaluated in siRNA-transfected U2OS cells using
quantitative reverse transcription PCR (qRT-PCR, Taq-
Man gene expression assay, ABI). Six of the fifteen genes
were increased less than 2-fold following TNFa stimula-
tion, confirming that NF-kB regulation of these genes is
cell type specific (Table S1). Among the nine genes that
were responsive to TNFa, loss of LZAP increased expres-
sion of IL-8 (9.9-fold), MMP-9 (6.9-fold), MCP-1 (3.3-fold),
Cox-2 (2.5-fold), and IkBa (2.2-fold) (Table S1). Increased
expression of MMP-9, IL-8, and MCP-1 was more than
additive following simultaneous TNFa stimulation and
LZAP knockdown.
LZAP Is Found on Selective NF-kB-Responsive
Promoters
Our data suggest that LZAP binds to RelA and inhibits
transcription without altering subcellular localization of
RelA. To determine if LZAP is within a DNA-associated
complex at NF-kB-responsive promoter sites, we per-
formed chromatin immunoprecipitation (ChIP) interrogat-
ing promoters of genes responsive to LZAP (MCP-1 and
IL-8), as well as one gene that responded to TNFa, but
not LZAP (cIAP-2). Following expression, LZAP was found
associatedwith theNF-kB-responsive elements ofMCP-1nc.
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(A) LZAP inhibits phosphorylation at serine 536 of RelA. U2OS cells were transfectedwith plasmids encodingMyc3-taggedRelA with or without LZAP.
After TNFa treatment, RelA protein was immunoprecipitated using mouse antibody (F6), and phosphorylated Myc3-tagged RelA was visualized by
immunoblotting with rabbit phosphospecific antibodies as indicated. The same membrane was stripped and reblotted with rabbit anti-RelA antibody
(C20). Exposure for visualization of serine 276-phosphorylated RelA was significantly longer relative to phosphoserine 529 or phosphoserine 536.
(B) Depletion of LZAP increases phosphorylation at serine 536 of endogenous RelA. Endogenous RelA phosphorylated at serine 536was visualized by
immunoblotting lysate prepared from U2OS cells left unstimulated or cells stimulated by TNFa or IL-1b following siRNA transfection. Total RelA was
immunoblotted after phosphoserine 536 RelA immunoblotting and stripping the membrane. LZAP and GAPDH were also immunoblotted.
(C) Mutation at serine 536 impairs LZAP inhibition of RelA-mediated transcription. U2OS cells were transfected with DNA constructs encoding Gal4-
fused wild-type RelA or RelA S536D mutant in the absence or presence of LZAP or IkBa-SR. Luciferase expression from a Gal4-dependent reporter
was determined.
(D) LZAP enhances RelA association with HDACs. U2OS cells were simultaneously transfected with control or LZAP-encoding plasmid and plasmid
encoding Myc3-tagged RelA as indicated. Immunoprecipitates were prepared with goat antibodies against HDAC1, HDAC2, or HDAC3, and immu-
noblotted with mouse anti-RelA antibody (F6).and IL-8 promoters, but not the cIAP-2 promoter
(Figure 7A). LZAP presence at IL-8 and MCP-1 promoters
was inhibited by coexpression of IkB-SR, suggesting that
LZAP association with these promoter sites was depen-
dent on NF-kB (Figure 7B). To determine if LZAP expres-
sion altered histone acetylation at NF-kB-responsive pro-
moter elements, ChIP using anti-acetyl histone 3
antibodies was performed. LZAP expression was associ-
ated with decreased histone 3 acetylation at MCP-1 and
IL-8 promoters, but not at the cIAP-2 promoter (Figure 7C).
LZAP Levels in Primary HNSCC Correlate with
Expression of IL-8 and IkBa
To determine if NF-kB-responsive gene expression dif-
fered between HNSCCs dependent on LZAP expression,
IL-8, IkBa, andMMP-9 expression wasmeasured by qRT-
PCR from tumors analyzed in Figure 1A. Gene expressionCancwas compared among the three groups of HNSCCs with
different LZAP protein levels: (1) similar LZAP expression
compared to NAT (similar, n = 16); (2) trace LZAP expres-
sion (trace, n = 4); and (3) undetectable LZAP expression
(undetectable, n = 5) (Figure 8). Data were normalized to
assign median expression in NAT as 1. Compared to the
group of HNSCCs with LZAP protein levels similar to
NAT, HNSCCs with undetectable LZAP protein contained
significantly higher expression of both IL-8 and IkBa, and
the group of HNSCC with low but detectable LZAP (trace)
also had higher IL-8 expression (Figure 8). MMP-9 was
elevated in all HNSCC groups compared to NAT but was
not significantly different between the HNSCC groups
based on LZAP expression. Comparison of IL-8, IkBa,
and MMP-9 expression with LZAP protein levels mea-
sured within individual HNSCCs revealed that decreasing
LZAP protein levels significantly correlated with increaseder Cell 12, 239–251, September 2007 ª2007 Elsevier Inc. 247
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(A) LZAP binds to NF-kB target DNA. U2OS cells were transfected with empty vector or plasmid encoding FLAG-tagged LZAP. After crosslinking,
LZAPwas precipitated by amouse anti-FLAG antibody, and associated NF-kB-targeted promoter regions of MCP-1, IL-8, and cIAP-2 were detected
by PCR.
(B) LZAP binding to NF-kB target DNA is inhibited by IkBa-SR. U2OS cells were transfected with empty vector or plasmids encoding FLAG-tagged
LZAP with or without IkBa-SR. LZAP binding to the NF-kB-targeted promoter regions of MCP-1 and IL-8 were determined as described above.
(C) LZAP is associatedwith reduced histone acetylation of specific NF-kB-responsive promoters. U2OS cells were infectedwith control adenovirus or
adenovirus expressing LZAP. ChIP analyses for indicated promoters were performed using antibody against histone 3 acetylated at lysine residues 9
and 14.IL-8 expression (Spearman correlation test, p = 0.001)
and also correlated with elevated IkBa expression (p =
0.0139). However, MMP-9 expression did not correlate
with LZAP protein levels in HNSCC (p = 0.30).
DISCUSSION
The NF-kB family of transcription factors regulates ex-
pression of a wide range of genes that are implicated in
many normal and protective biological processes, but is
also usurped during tumorigenesis. Related to cancer,
NF-kB regulates critical processes including apoptosis,
angiogenesis, invasion, metastasis, growth, and prolifera-
tion (Hayden and Ghosh, 2004; Kim et al., 2006). NF-kB
activity is tightly controlled through multiple mechanisms.
Classically, NF-kB is activated by nuclear translocation
triggered by phosphorylation-dependent degradation of
the IkB proteins. Once in the nucleus, NF-kB binds to kB
response elements and initiates transcription. A variety
of nuclear proteins, including p53, ARF, Twist, Smad3,
and Foxj1 regulate the strength, timing, and specificity of
NF-kB activity, as well as define crosstalk with other sig-
naling pathways (reviewed in Chen, 2004). Unlike IkB pro-
teins that sequester NF-kB in the cytoplasm, nuclear reg-
ulators work primarily through modification of NF-kB
proteins and by altering association of NF-kB with tran-
scriptional coregulators.248 Cancer Cell 12, 239–251, September 2007 ª2007 Elsevier IRecently, the activity of NF-kB as a transcriptional re-
pressor has also been recognized. In fact, conversion of
NF-kB to an active transcriptional repressor has been re-
ported as amechanism through which the tumor suppres-
sor ARF inhibits NF-kB. ARF expression results in inhibi-
tory phosphorylation at threonine 505 of RelA mediated
by the ATR-Chk1 pathway and increases association of
RelA with the transcription corepressor HDAC1 without
altering its DNA binding, thereby converting DNA-bound
NF-kB into a potential active transcriptional repressor
complex (Rocha et al., 2003, 2005). Additionally, Smad3,
p53, or chemotherapeutic agents, such as cisplatin, dau-
norubicin, and doxorubicin, selectively alter transcrip-
tional coregulators within NF-kB complexes, resulting in
NF-kB-mediated transcriptional repression. These obser-
vations suggest that DNA-bound NF-kB complexes can
be utilized to inhibit transcription under certain circum-
stance and that active repression contributes to overall
NF-kB regulation. Althoughwe have not formally excluded
the possibility that LZAP may alter RelA sequence-spe-
cific DNA binding, LZAP was found at the promoters of
NF-kB-responsive genes whose expression was altered
by LZAP, and these promoters had decreased acetylation
of histone 3 after LZAP expression. Additionally, expres-
sion of LZAP inhibited RelA transcription activity even in
the presence of cytokine-stimulated RelA nuclear translo-
cation andDNA binding (Figure 4, Figure 7, and Figure S1).nc.
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sion of LZAP resulted in decreased phosphorylation of
RelA serine 536 and increased association of RelA with
HDACs (Figure 6), suggest that RelA-containing NF-kB
complexes act as a transcription repressor, at least to-
ward certain NF-kB-responsive genes, in the presence
of LZAP. Depletion of endogenous LZAP increased NF-
kB transcription, suggesting a release of repression as in-
dicated by both increased NF-kB-mediated transcription
in reporter assays and upregulated expression of endog-
enous NF-kB-responsive genes such as MMP-9, IL-8,
and IkBa (Figure 2 and Table S1). LZAP directly binds
amino acids 195–350 of RelA by both in vivo and in vitro
assays (Figure 5). Within the LZAP interacting domain of
RelA is the dimerization domain, IkB-binding domain, nu-
clear localization signal (NLS), and several known amino
Figure 8. Loss of LZAP Protein Is Associated with Increased
mRNA Levels of NF-kB-Responsive Genes
Total RNA was extracted from 25 pairs of HNSCC tumors and normal
surrounding epithelia identical to those described in Figure 1A. Expres-
sion of IL-8, IkBa, and MMP-9 was determined by SYBR green-based
quantitative real-time PCR using derived cDNA and corrected for input
based on GAPDH expression. Data represent expression values of
each gene relative to the median of expression in normal epithelia ad-
jacent to tumor (NAT) (assigned as 1). Bars represented the median of
each data set. HNSCCswere divided into three groups based on LZAP
expression as described previously. The Mann-Whitney test was used
to compare differences in expression of NF-kB-responsive genes be-
tween HNSCCs with trace or undetectable LZAP expression and
HNSCCs with LZAP expression similar to NAT.Cancacid residues involved in regulation of RelA activity. These
regulatory sites include phosphor-acceptor sites, serine
residues 276 and 311, and acetyl-acceptor sites, lysine
residues 221 and 310. Modification of these sites has
been implicated in regulation of NF-kB, and potential ef-
fects of LZAP on these modification sites are currently
being explored.
Previous reports show that LZAP activates p53, result-
ing in cell cycle arrest and inhibition of clonogenic cell
growth (Wang et al., 2006), and that LZAP increases apo-
ptosis in response to etoposide through inappropriate
stimulation of CDK1/cyclin B activity (Jiang et al., 2005).
Here we ascribe other tumor suppressor-like activities to
LZAP, including suppression of cellular invasion, anchor-
age-independent growth, tumor growth, and angiogene-
sis. Our data show that LZAP protein was significantly re-
duced in 32% of head and neck squamous cell
carcinomas. As a surrogate marker for NF-kB activity, ex-
pression of three NF-kB-responsive genes was measured
in these tumors. Increased expression of two genes, IL-8
and IkBa, correlated with reduced LZAP expression in
HNSCC tumors (p < 0.05). NF-kB activity is increased in
HNSCC and can be regulated at multiple levels (Chang
and Van Waes, 2005; Chung et al., 2006). Correlation of
LZAP levels with expression of NF-kB-regulated genes
implies that LZAP may be an important regulator of
NF-kB activity in primary HNSCC.
Our data suggest that LZAP is a potent regulator of
basal and stimulated NF-kB activity and that loss of
LZAP promotes cellular activities associated with cancer
development. These data also support a role for LZAP in
tumorigenesis of human HNSCC and suggest that loss
of LZAP may contribute to increased NF-kB activity in
HNSCC. Additional studies in other tumor types, by eval-
uation for mechanisms of LZAP inactivation and creation
of a murine knockout model, will be necessary to confirm
tumor suppressor activities of LZAP and to determine reg-
ulators of LZAP levels or activity.
EXPERIMENTAL PROCEDURES
Plasmid Constructs
Luciferase reporters, 3kB-conA-luc, and conA-luc were generous gifts
from Dr. Neil Perkins (University of Dundee, Dundee, UK). Coding se-
quences of RelA or RelA truncation mutants were amplified by PCR
and subcloned into the BamHI and XhoI sites of the pcDNA3-Myc3 ex-
pression vector, RelA and RelA S536Dmutant were subcloned into the
BamHI and KpnI sites of pFA-CMV vector (Stratagene, La Jolla, CA),
p50 was subcloned into the EcoRI and XhoI sites of the pcDNA3-
Myc3 expression vector, and LZAP coding sequence was subcloned
into the KpnI and XbaI sites of the pET-His vector or the KpnI and
NotI sites of the pcDNA3-FLAG vector. Other DNA constructs were de-
scribed previously (Wang et al., 2006).
Antibodies and Reagents
Antibodies include mouse anti-RelA antibody F6, rabbit anti-RelA an-
tibody C20, rabbit anti-p50 antibody H119, goat anti-HDAC1 antibody
C19, goat anti-HDAC2 antibody C19, goat anti-HDAC3 antibody N19,
and rabbit anti-GAPDH antibody FL335, all from Santa Cruz Biotech-
nology (Santa Cruz, CA); rabbit anti-phospho-S276 and -S536 RelA
from Cell Signaling (Danvers, MA); rabbit anti-phospho-S529 RelA
from Biosource (Carlsbad, CA); mouse anti-FLAG antibody M2 fromer Cell 12, 239–251, September 2007 ª2007 Elsevier Inc. 249
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(Wang et al., 2006). TNFa and IL-1b were purchased from PeproTech
(Rocky Hill, NJ).
Cell Culture, Transfection, and Retroviral Infection
Mammalian tumor cell lines were maintained at 37C with 5% CO2, in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS) (Invitrogen, Carlsbad, CA). Human mammary epithelial
cells (TLM-HMEC), provided by Dr. William Hahn (Harvard University,
Cambridge, MA), were maintained in complete mammary epithelial
cell medium (MEGM, Cambrex, Baltimore, MD). Plasmids were trans-
fected by FuGene6 (Roche, Indianapolis, IN). The total amount of
transfected DNA in any single experiment was kept constant by adding
empty vector (pcDNA3). Small interfering RNA (siRNA) was transfected
at 20 nM by DharmaFECT 1 (Dharmacon, Chicago, IL). Control siRNA
duplex (nontargeting #1) was purchased from Dharmacon. The LZAP-
1 siRNA, 50-AAGGATTGGCAGGAGATTATA (sense strand), was
synthesized by QIAGEN and LZAP-2 siRNA with on-TARGETplus
modification, 50-CAAGGTATGTGGACCGAGT (sense strand), was
purchased from Dharmacon. Retrovirus interfering LZAP expression
was constructed by inserting LZAP-1 siRNA sequence into the
HindIII and BglII sites of pRetro-Super retroviral vector (provided by
Dr. Reuven Agami). Immunoprecipitation, indirect immunofluores-
cence, and luciferase assays have been previously described (Wang
et al., 2006).
Human Tumor Studies
Human head and neck squamous cell carcinomas were collected after
patient consent under an IRB-approved protocol (Head and neck tu-
mor tissue repository and clinical database, IRB #030062). Tumors
were flash frozen in liquid nitrogen within 30 min of excision and stored
at 80C until used.
Anchorage-Independent Growth Assay
TLM-HMEC cells (human mammary epithelial, stable expression of
hTERT and SV40 large T antigen, and elevated expression of endoge-
nous c-Myc) were infected with retrovirus expressing either control
shRNA or LZAP-specific shRNA, and selected with 4 mg/ml puromycin.
Cells (3 3 104) were seeded into 6-well plates with a bottom layer of
0.8% low-melting-temperature agar (SeaPlaque, Cambrex) in DMEM
and a top layer of 0.4% agar in MEGM. Colonies with greater than
50 mm diameter were scored after 2 weeks of growth.
In Vivo Tumorigenicity Assay
Female nude mice were purchased from Harlan (Indianapolis, IN). An-
imals were inoculated between 8 and 16weeks of age. HeLa cells were
infected by control retrovirus or retrovirus expressing LZAP-specific
shRNA, selected with puromycin, harvested, and resuspended in
PBS, and 1.5 3 106 cells were injected subcutaneously into both
flanks. Tumor diameter was measured weekly using calipers until the
largest tumors approached 15 mm. All procedures were performed
in accordance with an IACUC-approved protocol (IACUC# M/05/
048). Excised tumors were weighed, then portions were frozen in liquid
nitrogen or fixed in 4% paraformaldehyde before embedding in paraf-
fin. Hematoxylin and eosin staining and immunostaining of von Wille-
brand Factor (vWF) were performed by the Vanderbilt Immunohisto-
chemistry Core Laboratory. Density of blood vessels of xenograft
tumors was evaluated by two independent observers (magnification =
4003). Any stained endothelial cell or endothelial cell cluster that was
clearly separate from other stained endothelial cells was considered as
a single, countable vessel. At least eight high-powered fields were
counted for each tumor.
In Vitro Migration and Invasion Assays
Cell migration/invasion assays were performed using 24-well trans-
wells (8 mm pore size, Corning Life Sciences), coated with (invasion)
or without (migration) 60 ml 1 mg/ml matrigel (BD Sciences). U2OS cells
were starved in serum-free media overnight, trypsinized, and washed250 Cancer Cell 12, 239–251, September 2007 ª2007 Elsevier Ithree times in DMEM containing 1%FBS. Twenty thousand cells in 1%
FBS-DMEM were seeded into the upper chamber, and 600 ml DMEM
containing 10% or 1% FBS was placed in the lower chamber. After
16 hr incubation, matrigel and cells remaining in the upper chamber
were removed. Cells on the lower surface of the membrane were fixed
in 4% paraformaldehyde and stained with 0.5% crystal violet. Cells
in at least six random microscopic fields (2003 magnification) were
counted. All experiments were run in duplicate and were repeated
three times.
Zymography
Conditioned media were collected from U2OS cells after overnight
culture in serum-free media. Following one freeze and thaw cycle, 10
ml conditioned media of each sample was separated on 10% standard
polyacrylamide gel containing 0.1% gelatin under nonreducing condi-
tions. After electrophoresis, gels were washed twice for 15min in 2.5%
Triton X-100, then incubated for 12 hr in developing buffer (0.5 M Tris-
Hcl [pH 7.5], 10 mM CaCl2). Each gel was stained with 0.5% Coomas-
sie brilliant blue R-250 for 2 hr and destained in 50% methanol-10%
acetic acid.
In Vitro Protein-Binding Assay
In vitro transcription/translation (IVT) was performed in the pres-
ences of 35S-labeled methionine using TNT Quick Coupled Tran-
scription/Translation Systems (Promega, Madison WI). His6-tagged
LZAP was produced in bacteria and purified by Ni-NTA resin
(QIAGEN, Valencia, CA). IVT products were equally incubated with
excessive amount of His6-tagged LZAP bound to Ni-NTA resin or
Ni-NTA resin only for 2 hr at room temperature with gentle agitation.
Precipitates were washed with binding buffer (50 mM Tris [pH 8.0],
150 mM NaCl, 0.1% NP-40), and protein complexes associated with
Ni-NTA resin were separated on SDS-PAGE and visualized by auto-
radiography.
ChIP
ChIP assays were performed using the chromatin immunoprecipi-
tation assay kit (Upstate Biotechnology) according to the manufac-
turer’s instructions. The primers used to amplify MCP-1 promoter
were 50-CCCATTTGCTCATTTGGTCTCAGC and 50-GCTGCTGTC
TCTGCCTCTTATTGA, and the primers used to amplify IL-8 and
cIAP-2 promoter were previously described (Ashburner et al., 2001;
Hoberg et al., 2004).
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, two supplemental figures, and one supplemental table and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/12/3/239/DC1/.
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